Vascular endothelial growth factor in allergen-induced nasal inflammation

G. S. Choi, H. J. Park, Gyu Young Hur, S. J. Choi, S. Y. Shin, Y. M. Ye, H. S. Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background Increased vessel number and permeability are important features of the nasal mucosa in allergic rhinitis (AR), and are mediated in part by the cytokine vascular endothelial growth factor (VEGF). Eosinophils are the major effector cells in the nasal secretions of patients with AR during the responses to allergen challenges. To evaluate the involvement of VEGF in nasal allergic inflammation, we monitored the levels of VEGF, eosinophil cationic protein (ECP), and specific antibodies in the nasal lavage fluids (NLFs) of patients with AR in response to Dermatophagoides pteronyssinus (Dpt). Methods Sixty-three subjects with sensitization to Dpt were enrolled: 29 patients with AR (group I) who showed positive responses in a nasal provocation test (NPT) with Dpt; and 34 asymptomatic controls (group II) who showed sensitization to Dpt but negative NPT results. NLF samples were collected at baseline, 10, 30, and 60 min, and at 3, 6, and 24 h during the NPT. The ECP levels in the NLF samples were measured using the ImmunoCAP system. VEGF and Dpt-specific IgE, IgA, and IgG in the NLF samples were detected by ELISA. Results The eosinophil counts and ECP levels in the samples were significantly increased in group I, but not in group II, during the early and late responses. Although the baseline VEGF level was not significantly different between groups I and II, increased VEGF production was noted in group I after the NPT, especially during the early response. The level of Dpt-specific IgA was significantly increased in group I during the NPT. A relationship was found between the levels of VEGF and ECP or Dpt-specific IgA in the NLF samples collected at 10 min and at 3-6 h (P<0.05, respectively). Conclusion Nasal VEGF secretion in response to allergen exposure may augment eosinophilic inflammation in the nasal mucosa of patients with AR.

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalClinical and Experimental Allergy
Volume39
Issue number5
DOIs
Publication statusPublished - 2009 May 1

Fingerprint

Dermatophagoides pteronyssinus
Nose
Nasal Provocation Tests
Allergens
Nasal Lavage Fluid
Vascular Endothelial Growth Factor A
Eosinophil Cationic Protein
Inflammation
Immunoglobulin A
Nasal Mucosa
Eosinophils
Immunoglobulin E
Permeability
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Allergic Rhinitis
Cytokines
Control Groups
Antibodies

Keywords

  • Allergic rhinitis
  • Eosinophil
  • Nasal provocation
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Vascular endothelial growth factor in allergen-induced nasal inflammation. / Choi, G. S.; Park, H. J.; Hur, Gyu Young; Choi, S. J.; Shin, S. Y.; Ye, Y. M.; Park, H. S.

In: Clinical and Experimental Allergy, Vol. 39, No. 5, 01.05.2009, p. 655-661.

Research output: Contribution to journalArticle

Choi, G. S. ; Park, H. J. ; Hur, Gyu Young ; Choi, S. J. ; Shin, S. Y. ; Ye, Y. M. ; Park, H. S. / Vascular endothelial growth factor in allergen-induced nasal inflammation. In: Clinical and Experimental Allergy. 2009 ; Vol. 39, No. 5. pp. 655-661.
@article{d628b975cfca4fceb0a5d4eeeb094b30,
title = "Vascular endothelial growth factor in allergen-induced nasal inflammation",
abstract = "Background Increased vessel number and permeability are important features of the nasal mucosa in allergic rhinitis (AR), and are mediated in part by the cytokine vascular endothelial growth factor (VEGF). Eosinophils are the major effector cells in the nasal secretions of patients with AR during the responses to allergen challenges. To evaluate the involvement of VEGF in nasal allergic inflammation, we monitored the levels of VEGF, eosinophil cationic protein (ECP), and specific antibodies in the nasal lavage fluids (NLFs) of patients with AR in response to Dermatophagoides pteronyssinus (Dpt). Methods Sixty-three subjects with sensitization to Dpt were enrolled: 29 patients with AR (group I) who showed positive responses in a nasal provocation test (NPT) with Dpt; and 34 asymptomatic controls (group II) who showed sensitization to Dpt but negative NPT results. NLF samples were collected at baseline, 10, 30, and 60 min, and at 3, 6, and 24 h during the NPT. The ECP levels in the NLF samples were measured using the ImmunoCAP system. VEGF and Dpt-specific IgE, IgA, and IgG in the NLF samples were detected by ELISA. Results The eosinophil counts and ECP levels in the samples were significantly increased in group I, but not in group II, during the early and late responses. Although the baseline VEGF level was not significantly different between groups I and II, increased VEGF production was noted in group I after the NPT, especially during the early response. The level of Dpt-specific IgA was significantly increased in group I during the NPT. A relationship was found between the levels of VEGF and ECP or Dpt-specific IgA in the NLF samples collected at 10 min and at 3-6 h (P<0.05, respectively). Conclusion Nasal VEGF secretion in response to allergen exposure may augment eosinophilic inflammation in the nasal mucosa of patients with AR.",
keywords = "Allergic rhinitis, Eosinophil, Nasal provocation, Vascular endothelial growth factor (VEGF)",
author = "Choi, {G. S.} and Park, {H. J.} and Hur, {Gyu Young} and Choi, {S. J.} and Shin, {S. Y.} and Ye, {Y. M.} and Park, {H. S.}",
year = "2009",
month = "5",
day = "1",
doi = "10.1111/j.1365-2222.2009.03216.x",
language = "English",
volume = "39",
pages = "655--661",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Vascular endothelial growth factor in allergen-induced nasal inflammation

AU - Choi, G. S.

AU - Park, H. J.

AU - Hur, Gyu Young

AU - Choi, S. J.

AU - Shin, S. Y.

AU - Ye, Y. M.

AU - Park, H. S.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background Increased vessel number and permeability are important features of the nasal mucosa in allergic rhinitis (AR), and are mediated in part by the cytokine vascular endothelial growth factor (VEGF). Eosinophils are the major effector cells in the nasal secretions of patients with AR during the responses to allergen challenges. To evaluate the involvement of VEGF in nasal allergic inflammation, we monitored the levels of VEGF, eosinophil cationic protein (ECP), and specific antibodies in the nasal lavage fluids (NLFs) of patients with AR in response to Dermatophagoides pteronyssinus (Dpt). Methods Sixty-three subjects with sensitization to Dpt were enrolled: 29 patients with AR (group I) who showed positive responses in a nasal provocation test (NPT) with Dpt; and 34 asymptomatic controls (group II) who showed sensitization to Dpt but negative NPT results. NLF samples were collected at baseline, 10, 30, and 60 min, and at 3, 6, and 24 h during the NPT. The ECP levels in the NLF samples were measured using the ImmunoCAP system. VEGF and Dpt-specific IgE, IgA, and IgG in the NLF samples were detected by ELISA. Results The eosinophil counts and ECP levels in the samples were significantly increased in group I, but not in group II, during the early and late responses. Although the baseline VEGF level was not significantly different between groups I and II, increased VEGF production was noted in group I after the NPT, especially during the early response. The level of Dpt-specific IgA was significantly increased in group I during the NPT. A relationship was found between the levels of VEGF and ECP or Dpt-specific IgA in the NLF samples collected at 10 min and at 3-6 h (P<0.05, respectively). Conclusion Nasal VEGF secretion in response to allergen exposure may augment eosinophilic inflammation in the nasal mucosa of patients with AR.

AB - Background Increased vessel number and permeability are important features of the nasal mucosa in allergic rhinitis (AR), and are mediated in part by the cytokine vascular endothelial growth factor (VEGF). Eosinophils are the major effector cells in the nasal secretions of patients with AR during the responses to allergen challenges. To evaluate the involvement of VEGF in nasal allergic inflammation, we monitored the levels of VEGF, eosinophil cationic protein (ECP), and specific antibodies in the nasal lavage fluids (NLFs) of patients with AR in response to Dermatophagoides pteronyssinus (Dpt). Methods Sixty-three subjects with sensitization to Dpt were enrolled: 29 patients with AR (group I) who showed positive responses in a nasal provocation test (NPT) with Dpt; and 34 asymptomatic controls (group II) who showed sensitization to Dpt but negative NPT results. NLF samples were collected at baseline, 10, 30, and 60 min, and at 3, 6, and 24 h during the NPT. The ECP levels in the NLF samples were measured using the ImmunoCAP system. VEGF and Dpt-specific IgE, IgA, and IgG in the NLF samples were detected by ELISA. Results The eosinophil counts and ECP levels in the samples were significantly increased in group I, but not in group II, during the early and late responses. Although the baseline VEGF level was not significantly different between groups I and II, increased VEGF production was noted in group I after the NPT, especially during the early response. The level of Dpt-specific IgA was significantly increased in group I during the NPT. A relationship was found between the levels of VEGF and ECP or Dpt-specific IgA in the NLF samples collected at 10 min and at 3-6 h (P<0.05, respectively). Conclusion Nasal VEGF secretion in response to allergen exposure may augment eosinophilic inflammation in the nasal mucosa of patients with AR.

KW - Allergic rhinitis

KW - Eosinophil

KW - Nasal provocation

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=64649090866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64649090866&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2222.2009.03216.x

DO - 10.1111/j.1365-2222.2009.03216.x

M3 - Article

C2 - 19236408

AN - SCOPUS:64649090866

VL - 39

SP - 655

EP - 661

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 5

ER -